Equities Analysts Offer Predictions for CMPX FY2025 Earnings

Key Points

• Compass Therapeutics, Inc. has seen a downgrade in FY2025 earnings per share estimates by Leerink Partners, now projected at ($0.58) compared to the prior estimate of ($0.56).
• Despite the earnings downgrade, the company maintains a consensus target price of $12.89 with multiple analysts issuing "buy" ratings on the stock.
• The company's stock currently trades at $3.04, with a market cap of approximately $419.69 million and significant involvement from institutional investors holding over 68% of shares.

Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) - Leerink Partnrs cut their FY2025 earnings per share estimates for Compass Therapeutics in a research note issued to investors on Monday, August 11th. Leerink Partnrs analyst A. Berens now anticipates that the company will post earnings per share of ($0.58) for the year, down from their prior forecast of ($0.56). The consensus estimate for Compass Therapeutics' current full-year earnings is ($0.36) per share. Leerink Partnrs also issued estimates for Compass Therapeutics' FY2026 earnings at ($0.76) EPS and FY2027 earnings at ($0.85) EPS.

A number of other equities research analysts also recently commented on CMPX. D. Boral Capital reaffirmed a "buy" rating and set a $32.00 target price on shares of Compass Therapeutics in a report on Tuesday. Raymond James Financial raised Compass Therapeutics to an "outperform" rating and set a $9.00 price target for the company in a report on Tuesday, July 1st. Guggenheim boosted their price target on Compass Therapeutics from $10.00 to $12.00 and gave the company a "buy" rating in a report on Tuesday. Finally, HC Wainwright reissued a "buy" rating and issued a $24.00 price target on shares of Compass Therapeutics in a report on Monday, April 21st. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $12.89.

Compass Therapeutics Price Performance

NASDAQ CMPX traded down $0.07 during trading on Thursday, hitting $3.04. The company's stock had a trading volume of 137,034 shares, compared to its average volume of 1,410,221. The company has a market cap of $419.69 million, a PE ratio of -6.74 and a beta of 1.49. The business's 50 day simple moving average is $2.78 and its 200-day simple moving average is $2.50. Compass Therapeutics has a fifty-two week low of $1.15 and a fifty-two week high of $4.08.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last issued its quarterly earnings results on Monday, August 11th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.01).

Institutional Trading of Compass Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. MPM Bioimpact LLC grew its holdings in Compass Therapeutics by 51.9% in the 4th quarter. MPM Bioimpact LLC now owns 8,567,896 shares of the company's stock valued at $12,423,000 after buying an additional 2,926,002 shares in the last quarter. Enavate Sciences GP LLC acquired a new position in shares of Compass Therapeutics in the 4th quarter valued at $11,293,000. Vivo Capital LLC lifted its stake in shares of Compass Therapeutics by 70.0% in the 2nd quarter. Vivo Capital LLC now owns 6,043,466 shares of the company's stock valued at $15,713,000 after purchasing an additional 2,487,443 shares during the last quarter. Tang Capital Management LLC lifted its stake in shares of Compass Therapeutics by 225.4% in the 4th quarter. Tang Capital Management LLC now owns 5,900,000 shares of the company's stock valued at $8,555,000 after purchasing an additional 4,087,005 shares during the last quarter. Finally, Rock Springs Capital Management LP lifted its stake in shares of Compass Therapeutics by 2.7% in the 4th quarter. Rock Springs Capital Management LP now owns 5,779,575 shares of the company's stock valued at $8,380,000 after purchasing an additional 150,336 shares during the last quarter. 68.43% of the stock is currently owned by hedge funds and other institutional investors.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.